Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD

NCT00403442 is registered in ClinicalTrials.gov with Vitreous -Retina- Macula Consultants of New York as lead sponsor.

NCT NCT00403442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00403442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD
Lead sponsor
Vitreous -Retina- Macula Consultants of New York
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2006
Completion date
Not reported
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

macular degeneration